The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Pivekimab sunirine w/ venetoclax + azacitidine in unfit patients with newly diagnosed AML
Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase Ib/II study (NCT04086264) evaluating the efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML). The study demonstrated significantly improved response rates with the addition of pivekimab sunrine, with ongoing evaluation of measurable residual disease (MRD) and survival outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
